Cimzia (certolizumab pegol) / Astellas, UCB 
Welcome,         Profile    Billing    Logout  
 50 Diseases   29 Trials   29 Trials   3299 News 


«12...1819202122232425262728...3839»
  • ||||||||||  Cimzia (certolizumab pegol) / Astellas, UCB, Eli Lilly
    [VIRTUAL] Budget IMPACT Analysis of a Reduced Maintenance Dose of Certolizumab Pegol in Patients with Axial Spondyloarthritis in the United Kingdom () -  Oct 3, 2020 - Abstract #ISPOREU2020ISPOR-EU_1628;    
    P3
    Overall, net savings with RMD were £13.33 million, out of £627.17 million total spend in the FMD scenario. Scenario analysis of RMD suggested that cost savings were still realised within reasonable CZP market share uptake assumptions.CONCLUSIONS : CZP RMD for axSpA patients in sustained remission led to net savings compared to continuing FMD regimen in the UK, due to lower overall cost of treatment despite a marginal direct cost increase associated with marginally higher risk of disease flare.
  • ||||||||||  Humira (adalimumab) / Eisai, AbbVie, Cimzia (certolizumab pegol) / Astellas, UCB, Eli Lilly
    [VIRTUAL] An Indirect Comparison of Sustained Remission and FLARE Rates in Responders with NON-Radiographic Axial Spondyloarthritis (NR-AXSPA) () -  Oct 3, 2020 - Abstract #ISPOREU2020ISPOR-EU_1299;    
    In ABILITY-3, patients responding to 28 weeks of adalimumab (ADA) 40mg Q2W were randomised to ADA 40mg Q2W or PBO...Patients receiving CZP 200mg Q2W and CZP 200mg Q4W had significantly lower odds of flares 48 weeks post-randomisation compared to ADA at 40 weeks (OR [95% CrI]: 0.15 [0.05–0.44] and 0.25 [0.08–0.69], respectively). CONCLUSIONS : In nr-axSpA patients who responded to TNFi regimens, continued CZP treatment at both full and reduced maintenance doses showed improved odds of reduced flares and sustained remission compared to continued ADA.
  • ||||||||||  [VIRTUAL] Health-Economic Analysis of Tocilizumab in Patients with Rheumatoid Arthritis and Systemic Juvenile Arthritis () -  Oct 3, 2020 - Abstract #ISPOREU2020ISPOR-EU_604;    
    Tocilizumab was less costly comparing to adalimumab (Humira), certolizumab pegol, golimumab by 12.8%, 14.5%, 10,0%, consequently...Tocilizumab was more costly comparing to adalimumab (Dalibra) etanercept, infliximab (Remicade) by 5.6%, 7.7%, 3.9 %, consequently...The share of bDMARDs in total costs structure was 84%-96%. CONCLUSIONS Tocilizumab is economically reasonable comparing to others TNF-α inhibitors in patients with RA and sJA.
  • ||||||||||  [VIRTUAL] Budget IMPACT Analysis of Secukinumab in the Treatment of Ankylosing Spondylitis By the Biological Therapy in the Russian Federation () -  Oct 3, 2020 - Abstract #ISPOREU2020ISPOR-EU_339;    
    With the current distribution of patients, adalimumab received 26%, golimumab - 14%, infliximab - 26%, etanercept 18%, certolizumab pegol 7%, secukinumab - 9%...Also, in the simulated distribution, the shares of recently registered drugs - netakimab - 6.8%, and ixekizumab - 2.6% were taken into account...Thus, when calculating per 100 patients, the simulated distribution of patients in comparison with the current one provided savings in the amount of €102 335 in the first year and €226 936 for three years. CONCLUSIONS : From budget impact analysis perspective increasing share of secukinumab in the treatment of ankylosing spondylitis by the biological therapy provided cost-savings.
  • ||||||||||  Cimzia (certolizumab pegol) / Astellas, UCB
    New trial:  Treatment of Pregnancy RA (clinicaltrials.gov) -  Sep 29, 2020   
    P=N/A,  N=100, Not yet recruiting, 
  • ||||||||||  Cimzia (certolizumab pegol) / Astellas, UCB
    Trial completion, Trial completion date, Trial primary completion date:  SECURE, the Cimzia  (clinicaltrials.gov) -  Sep 28, 2020   
    P=N/A,  N=3045, Completed, 
    Active, not recruiting --> Terminated; Low enrollment Active, not recruiting --> Completed | Trial completion date: Aug 2025 --> Aug 2020 | Trial primary completion date: Aug 2025 --> Aug 2020
  • ||||||||||  Cimzia (certolizumab pegol) / Astellas, UCB
    Trial completion date, Trial primary completion date:  Pediatric Arthritis Study of Certolizumab Pegol (clinicaltrials.gov) -  Sep 18, 2020   
    P3,  N=163, Active, not recruiting, 
    When selecting bDMARD in each case, it is necessary to take into account the continuity at all stages of treatment. Trial completion date: Jun 2023 --> Dec 2023 | Trial primary completion date: Jun 2023 --> Dec 2023
  • ||||||||||  Remicade (infliximab) / Mitsubishi Tanabe, J&J, Humira (adalimumab) / Eisai, AbbVie, Cimzia (certolizumab pegol) / Astellas, UCB, Eli Lilly
    [VIRTUAL] Acute Leukocytoclastic Vasculitis: A Rare Adverse Reaction to Certolizumab Pegol Therapy in a Patient With Crohn’s Disease () -  Sep 15, 2020 - Abstract #ACG2020ACG_2344;    
    Three months later, his behavior returned back to normal; he was subsequently trialed on a few other regimens (including Adalimumab, Methotrexate and Mesalamine) but again experienced a myriad of side effects...Acute LCV is (per our literature review) a rarely reported side effect. Gastroenterologists, primary care providers, rheumatologists and dermatologists should be aware of this potential side effect and consider cessation of the drug if necessary.
  • ||||||||||  Cimzia (certolizumab pegol) / Astellas, UCB, Eli Lilly
    [VIRTUAL] Aseptic Liver Abscesses in a Crohn's Patient - True Infection or a Crohn's Flare!! () -  Sep 15, 2020 - Abstract #ACG2020ACG_2316;    
    He had been on Certolizumab for his Crohn’s disease and it was uncontrolled with frequent flares...Relapse rate for AA is very high, approaching 70 percent. Whether recurrent aseptic abscesses should be identified as a crohn’s flare and not a true infection is not yet defined and is an important topic of research at this point.
  • ||||||||||  Cimzia (certolizumab pegol) / Astellas, UCB, Eli Lilly
    [VIRTUAL] Colitis in a Rheumatologic Patient () -  Sep 15, 2020 - Abstract #ACG2020ACG_1141;    
    Patients with rheumatologic diseases are often on medications with adverse gastrointestinal effects, including biologics, steroids, NSAIDs and other immunomodulators. The lack of randomized studies, vague radiologic, endoscopic and histologic findings, as well as the variable onset after medication initiation makes leflunomide-induced colitis a challenging and rare diagnosis.